Navigation Links
Mayo Clinic Researchers Say Triple Drug Combination is Promising Option to Treat Metastatic HER2+ Breast Cancer
Date:5/18/2009

regimen does not offer curative treatment, but it offers patients an improved quality of life compared to other commonly used regimens.

"It is very difficult to treat cancer that has spread, but we believe that combining treatments together is important to help shrink tumors that are rapidly growing," he says.

He adds that 80 percent of the patients who showed benefit had been treated with other chemotherapy drugs -- mostly anthracyclines and paclitaxel -- and at least half of the patients had used trastuzumab in the adjuvant or metastatic setting as well. "They still got a response to these combination of two chemotherapies plus the biological agent, and that is encouraging," he says.

About Mayo Clinic

Mayo Clinic is the first and largest integrated, not-for-profit group practice in the world. Doctors from every medical specialty work together to care for patients, joined by common systems and a philosophy of "the needs of the patient come first." More than 3,300 physicians, scientists and researchers and 46,000 allied health staff work at Mayo Clinic, which has sites in Rochester, Minn., Jacksonville, Fla., and Scottsdale/Phoenix, Ariz. Collectively, the three locations treat more than half a million people each year. To obtain the latest news releases from Mayo Clinic, go to www.mayoclinic.org/news. For information about research and education, visit www.mayo.edu. MayoClinic.com (www.mayoclinic.com) is available as a resource for your health stories.


'/>"/>
SOURCE Mayo Clinic
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Two Targeted Therapies Likely Better Than One in Patients with Aggressive Lymphoma, Mayo Clinic Researchers Say
2. Mayo Clinic Researchers Say Agent Provides Treatment Option for Women with Hot Flashes
3. Drug That Targets Vasculature Growth Attacks Aggressive Thyroid Cancer, Mayo Clinic Researchers Report
4. Fate Therapeutics Adds Pratik Multani, M.D., M.S., as Vice President Clinical Development to Advance Upcoming Clinical Programs of Stem Cell Modulators
5. InDex Pharmaceuticals AB Engages PharmaVentures to Facilitate the Licensing of Kappaproct(R) After Phase IIa Trial Achieves Clinical Endpoints Early
6. Frost & Sullivan: Clinical and Cost Benefits to Promote Uptake of Advanced Wound Management Technologies Across Europe
7. Large clinical trial finds pirfenidone may help lung function in IPF patients
8. Fewer Than One Percent of Infertile Couples Who Need Treatment Receive It - Website to Bridge Gap Between Infertile Couples and Fertility Clinics
9. Cleveland Clinic CIO Named to Federal Advisory Committee on Health Information Technology
10. BioVex To Announce Updated Survival Data From a Phase II Clinical Study of OncoVEX GM-CSF in Metastatic Melanoma at The 2009 American Society of Clinical Oncology Meeting
11. Cigna Medical Group Announces Grand Opening of CareToday Clinic in Anthem, Ariz.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2014)... 01, 2014 The National Association of ... that Dawn Bazarko, DNP, MPH, RN, and Adriana Perez, ... American Academy of Nursing. They will be inducted with ... FACHE, whose induction we reported last May. , Our ... during the 2014 American Academy of Nursing Policy Conference ...
(Date:9/1/2014)... Registration is now open for the 4th Annual ... to be held on Sunday, September 21, 2014. The event ... Meadow in Secaucus, New Jersey. All proceeds from the race ... to restoring a sense of self, restoring the family unit, ... families. , General registration is $30 with special pricing for ...
(Date:9/1/2014)... San Diego, CA (PRWEB) September 01, 2014 ... website daily regarding all the latest information from the ... , The US FDA announced on August 28, ... are recalled (Class I) as the device ... FDA, the DePuy Synthes Craniomaxillofacial (CMF) Distraction System is ...
(Date:9/1/2014)... (PRWEB) September 01, 2014 ... into Heartbeat Experts’ perspectives on stakeholder ... , Download the flash report to speak ... any launching Diabetes product:, , ... an increasingly crowded market ,     Understanding ...
(Date:8/31/2014)... 31, 2014 Just in time for Washington’s ... only wild, sustainable Alaska Salmon, award winning chowder ... Duke's Green Lake location , Sunday, September 28, 2014 ... sample several ethnic salmon BBQ culinary delights. Live music will ... from Hawaii, Puerto Rico and Mexico will be featured. ...
Breaking Medicine News(10 mins):Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 2Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 3Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 4Health News:Hope For The Warriors New Jersey Run to Honor Wounded and Families of the Fallen 2Health News:DePuy Synthes Craniomaxillofacial Distraction System Recalled (Class I): AttorneyOne Monitors and Keeps Consumers Informed 2Health News:DePuy Synthes Craniomaxillofacial Distraction System Recalled (Class I): AttorneyOne Monitors and Keeps Consumers Informed 3Health News:Download HeartBeat Experts White Paper: Stakeholder Management for new Diabetes Products 2Health News:Seattle Seafood Restaurant Duke's Chowder House on Green Lake Will Celebrate The Long Anticipated Indian Summer With First Annual Sizzling BBQ Salmon Tasting Event. 2
... ... and Insurance Services, a leading provider of information-based technology services to the ... in Louisiana and Texas in addition to its services that are provided ... headquartered in Hampton, New Hampshire and is owned by Medical Protective, part ...
... , , ARLINGTON, Va., ... that a panel of independent scientific experts convened by the ... a reproductive or developmental toxicant. After a thorough review ... Committee determined that bisphenol A should not be listed under ...
... WASHINGTON, July 15 On behalf of the nation,s mayors, ... commended President Barack Obama, the House of Representatives and the Senate ... transformative health care reform legislation. , ... times because they are not able to afford health insurance and, ...
... , SCOTTSDALE, Ariz., July 15 Grubb ... of America, Inc.) (the "REIT"), a self-managed non-traded real estate ... agreement (the "Agreement") to acquire a 16 building portfolio from ... transaction involves approximately 855,000 square feet of medical office and ...
... , , CARY, N.C., ... CRTX ), a specialty pharmaceutical company focused on acquiring, ... and related markets, today announced that it has submitted ... Administration (FDA) for an extended-release antitussive product (CRTX 067) ...
... , , , ... presented today, the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory ... and docetaxel did not provide a sufficient benefit-risk ... cancer. , , Women with locally advanced ...
Cached Medicine News:Health News:Garnet Health -- A Leader in the Healthcare Industry Expands its Operations 2Health News:Garnet Health -- A Leader in the Healthcare Industry Expands its Operations 3Health News:California Expert Panel Concludes Bisphenol A is Not a Reproductive or Developmental Toxicant 2Health News:The Nation's Mayors Commend New Healthcare Reform Legislation 2Health News:Grubb & Ellis Healthcare REIT Signs Agreement to Purchase 16 Building Medical Office Portfolio 2Health News:Grubb & Ellis Healthcare REIT Signs Agreement to Purchase 16 Building Medical Office Portfolio 3Health News:Cornerstone Therapeutics Submits Regulatory Filing for Extended-Release Antitussive Product 2Health News:Cornerstone Therapeutics Submits Regulatory Filing for Extended-Release Antitussive Product 3Health News:Cornerstone Therapeutics Submits Regulatory Filing for Extended-Release Antitussive Product 4Health News:Cornerstone Therapeutics Submits Regulatory Filing for Extended-Release Antitussive Product 5Health News:Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer 2Health News:Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer 3Health News:Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer 4Health News:Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer 5Health News:Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer 6
(Date:8/29/2014)... , August 29, 2014 ... Seed Oil Market by Extraction type (SFE, Cold ... & Personal Care, Pharmaceutical, Food Supplements, Fragrance, & Others) ... by MarketsandMarkets, defines and segments the Amaranth Seed ... the market size in terms of value. The ...
(Date:8/29/2014)... , Aug. 29, 2014  United Therapeutics Corporation ... U.S. District Court for the District of ... in the company,s case against Sandoz, Inc. regarding United ... Peter Sheridan ruled that U.S. Patent No. 6,765,117 ... enjoined Sandoz from marketing its generic product until the ...
(Date:8/29/2014)... , Aug. 29, 2014 Diseases largely ... a generation ago are returning. Measles was declared eliminated ... in 2014 as of August 15—the highest incidence in ... public health department declared whooping cough a problem of ... are getting sick and dying from these preventable diseases—in ...
Breaking Medicine Technology:Amaranth Seed Oil Market worth $700.6 Million by 2019 2Amaranth Seed Oil Market worth $700.6 Million by 2019 3Amaranth Seed Oil Market worth $700.6 Million by 2019 4District Court Decision Received In Remodulin Patent Case 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 3
... CINCINNATI, July 7 Procter & Gamble Pharmaceuticals (P&GP) ... tablets, which are indicated for the treatment of moderately ... disease. UC involves inflammation of the lining of the ... followed by periods of remission. Moderately active UC is ...
... Tenn., July 6 /PRNewswire/ -- A Pebble Beach ... cure for multiple sclerosis. The researchers took home the top ... and the non-profit Band Against MS (BAMS) organization. The money ... at the University of Texas Health Science Center at ...
Cached Medicine Technology:Procter & Gamble Pharmaceuticals Launches Asacol(R) HD (mesalamine) Delayed-Release Tablets 2Procter & Gamble Pharmaceuticals Launches Asacol(R) HD (mesalamine) Delayed-Release Tablets 3Procter & Gamble Pharmaceuticals Launches Asacol(R) HD (mesalamine) Delayed-Release Tablets 4Procter & Gamble Pharmaceuticals Launches Asacol(R) HD (mesalamine) Delayed-Release Tablets 5Clay Walker's Band Against MS Foundation Donates $150,000 To Support Multiple Sclerosis Research 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: